Effects of prolonged treatment of TGF-βR inhibitor SB431542 on radiation-induced signaling in breast cancer cells

References

• Anestakis D, Petanidis S, Kalyvas S, Nday CM, Tsave O, Kioseoglou E, Salifoglou A. 2015. Mechanisms and applications of interleukins in cancer immunotherapy. Int J Mol Sci. 16(1):1691–710.
   PubMed Web of Science ®Google Scholar
• Anscher MS, Crocker IR, Jirtle RL. 1990. Transforming growth factor-beta 1 expression in irradiated liver. Radiat Res. 122(1):77–85.
   PubMed Web of Science ®Google Scholar
• Atun R, Jaffray DA, Barton MB, Bray F, Baumann M, Vikram B, Hanna TP, Knaul FM, Lievens Y, Lui TY, et al. 2015. Expanding global access to radiotherapy. Lancet Oncol. 16(10):1153–1186.
   PubMed Web of Science ®Google Scholar
• Avtanski DB, Nagalingam A, Bonner MY, Arbiser JL, Saxena NK, Sharma D. 2014. Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis. Mol Oncol. 8(3):565–580.
   PubMed Web of Science ®Google Scholar
• Bai M, Ma X, Li X, Wang X, Mei Q, Li X, Wu Z, Han W. 2015. The Accomplices of NF-κB Lead to Radioresistance. Curr Protein Pept Sci. 16(4):279–294.
   PubMed Web of Science ®Google Scholar
• Barthelemy-Brichant N, Bosquée L, Cataldo D, Corhay J-L, Gustin M, Seidel L, Thiry A, Ghaye B, Nizet M, Albert A, et al. 2004. Increased IL-6 and TGF-beta1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy. Int J Radiat Oncol Biol Phys. 58(3):758–767.
   PubMed Web of Science ®Google Scholar
• Baugé C, Cauvard O, Leclercq S, Galéra P, Boumédiene K. 2011. Modulation of transforming growth factor beta signalling pathway genes by transforming growth factor beta in human osteoarthritic chondrocytes: involvement of Sp1 in both early and late response cells to transforming growth factor beta. Arthritis Res Ther. 13(1):R23.
   PubMed Web of Science ®Google Scholar
• Baumann M, Krause M, Overgaard J, Debus J, Bentzen SM, Daartz J, Richter C, Zips D, Bortfeld T. 2016. Radiation oncology in the era of precision medicine. Nat Rev Cancer. 16(4):234–249.
   PubMed Web of Science ®Google Scholar
• Belenkov AI, Shenouda G, Rizhevskaya E, Cournoyer D, Belzile JP, Souhami L, Devic S, Chow TY. 2004. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther. 3(12):1525–1532.
   PubMed Web of Science ®Google Scholar
• Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, Gagliardini E, Rottoli D, Zanchi C, Abbate M, et al. 2003. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol. 14(7):1816–1824.
   PubMed Web of Science ®Google Scholar
• Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML, Arteaga CL. 2007. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest. 117(5):1305–1313.
   PubMed Web of Science ®Google Scholar
• Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, Balasubramaniam A, Nair S, Oliushine V, Parfenov V, Trabedersen Glioma Study Group, et al. 2011. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 13(1):132–142.
   PubMed Web of Science ®Google Scholar
• Canney PA, Dean S. 1990. Transforming growth factor beta: a promotor of late connective tissue injury following radiotherapy? Br J Radiol. 63(752):620–623.
   PubMed Web of Science ®Google Scholar
• Cataldi A, di Giacomo V, Rapino M, Genovesi D, Rana RA. 2006. Cyclic nucleotide Response Element Binding protein (CREB) activation promotes survival signal in human K562 erythroleukemia cells exposed to ionising radiation/etoposide combined treatment. J Radiat Res. 47(2):113–120.
   PubMed Web of Science ®Google Scholar
• Chakraborty P, George JT, Tripathi S, Levine H, Jolly MK. 2020. Comparative Study of Transcriptomics-Based Scoring Metrics for the Epithelial-Hybrid-Mesenchymal Spectrum [10.3389/fbioe.2020.00220]. Front Bioeng Biotechnol. 8:220.
   PubMed Web of Science ®Google Scholar
• Connolly EC, Saunier EF, Quigley D, Luu MT, De Sapio A, Hann B, Yingling JM, Akhurst RJ. 2011. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761. Cancer Res. 71(6):2339–2349.
   PubMed Web of Science ®Google Scholar
• Cui J, Placzek WJ. 2018. Post-transcriptional regulation of anti-apoptotic BCL2 family members. Int J Mol Sci. 19(1):308–330.
   Web of Science ®Google Scholar
• Derynck R, Zhang YE. 2003. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 425(6958):577–584.
   PubMed Web of Science ®Google Scholar
• Domina EA, Philchenkov A, Dubrovska A. 2018. Individual Response to Ionizing Radiation and Personalized Radiotherapy. Crit Rev Oncog. 23(1-2):69–92.
   PubMedGoogle Scholar
• Dong W, Sun S, Cao X, Cui Y, Chen A, Li X, Zhang J, Cao J, Wang Y. 2017. Exposure to TNF‑α combined with TGF‑β induces carcinogenesis in vitro via NF-κB/Twist axis. Oncol Rep. 37(3):1873–1882.
   PubMed Web of Science ®Google Scholar
• Duan D, Derynck R. 2019. Transforming growth factor-β (TGF-β)-induced up-regulation of TGF-β receptors at the cell surface amplifies the TGF-β response. J Biol Chem. 294(21):8490–8504.
   PubMed Web of Science ®Google Scholar
• Feng H, Xiang H, Mao YW, Wang J, Liu JP, Huang XQ, Liu Y, Liu SJ, Luo C, Zhang XJ, et al. 2004. Human Bcl-2 activates ERK signaling pathway to regulate activating protein-1, lens epithelium-derived growth factor and downstream genes. Oncogene. 23(44):7310–7321.
   PubMed Web of Science ®Google Scholar
• Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P. 2010. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol. 10(8):554–567.
   PubMed Web of Science ®Google Scholar
• Grdina DJ, Murley JS, Miller RC, Woloschak GE, Li JJ. 2015. NFκB and Survivin-Mediated Radio-Adaptive Response. Radiat Res. 183(4):391–397.
   PubMed Web of Science ®Google Scholar
• Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, Morris M, Wyatt L, Farshid G, Lim YY, et al. 2011. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell. 22(10):1686–1698.
   PubMed Web of Science ®Google Scholar
• Halder SK, Beauchamp RD, Datta PK. 2005. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia. 7(5):509–521.
   PubMed Web of Science ®Google Scholar
• Huang S, Xie K, Bucana CD, Ullrich SE, Bar-Eli M. 1996. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res. 2(12):1969–1979.
   PubMed Web of Science ®Google Scholar
• Hui L, Zheng Y, Yan Y, Bargonetti J, Foster DA. 2006. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene. 25(55):7305–7310.
   PubMed Web of Science ®Google Scholar
• Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. 2002. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 62(1):65–74.
   PubMed Web of Science ®Google Scholar
• Jolly MK, Boareto M, Huang B, Jia D, Lu M, Ben-Jacob E, Onuchic JN, Levine H. 2015. Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis. Front Oncol. 5:155.
   PubMed Web of Science ®Google Scholar
• Jolly MK, Somarelli JA, Sheth M, Biddle A, Tripathi SC, Armstrong AJ, Hanash SM, Bapat SA, Rangarajan A, Levine H. 2019. Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. Pharmacol Ther. 194:161–184.
   PubMed Web of Science ®Google Scholar
• Kale J, Osterlund EJ, Andrews DW. 2018. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 25(1):65–80.
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim SC, Kim SJ, Park CH, Jeung HC, Kim YB, Ahn JB, Chung HC, Rha SY. 2012. Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells. BMC Genomics. 13:348.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim JH, Lee GE, Kim SW, Chung IK. 2003. Identification of a quinoxaline derivative that is a potent telomerase inhibitor leading to cellular senescence of human cancer cells. Biochem J. 373(Pt 2):523–529.
   PubMedGoogle Scholar
• Kundu N, Beaty TL, Jackson MJ, Fulton AM. 1996. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst. 88(8):536–541.
   PubMedGoogle Scholar
• Li YL, Chang JT, Lee LY, Fan KH, Lu YC, Li YC, Chiang CH, You GR, Chen HY, Cheng AJ. 2017. GDF15 contributes to radioresistance and cancer stemness of head and neck cancer by regulating cellular reactive oxygen species via a SMAD-associated signaling pathway. Oncotarget. 8(1):1508–1528.
   PubMedGoogle Scholar
• Llorens MC, Lorenzatti G, Cavallo NL, Vaglienti MV, Perrone AP, Carenbauer AL, Darling DS, Cabanillas AM. 2016. Phosphorylation Regulates Functions of ZEB1 Transcription Factor. J Cell Physiol. 231(10):2205–2217.
   PubMed Web of Science ®Google Scholar
• Long J, Zuo D, Park M. 2005. Pc2-mediated sumoylation of Smad-interacting protein 1 attenuates transcriptional repression of E-cadherin. J Biol Chem. 280(42):35477–35489.
   PubMed Web of Science ®Google Scholar
• Massagué J. 1998. TGF-beta signal transduction. Annu Rev Biochem. 67:753–791.
   PubMed Web of Science ®Google Scholar
• Mourskaia AA, Dong Z, Ng S, Banville M, Zwaagstra JC, O'Connor-McCourt MD, Siegel PM. 2009. Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone. Oncogene. 28(7):1005–1015.
   PubMed Web of Science ®Google Scholar
• Munro AJ. 2009. Bystander effects and their implications for clinical radiotherapy. J Radiol Prot. 29(2A):A133–142.
   PubMed Web of Science ®Google Scholar
• Nam J-S, Suchar AM, Kang M-J, Stuelten CH, Tang B, Michalowska AM, Fisher LW, Fedarko NS, Jain A, Pinkas J, et al. 2006. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res. 66(12):6327–6335.
   PubMed Web of Science ®Google Scholar
• Noordhuis MG, Eijsink JJ, Ten Hoor KA, Roossink F, Hollema H, Arts HJ, Pras E, Maduro JH, Reyners AK, de Bock GH, et al. 2009. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res. 15(23):7389–7397.
   PubMed Web of Science ®Google Scholar
• Ozeki M, Tamae D, Hou DX, Wang T, Lebon T, Spitz DR, Li JJ. 2004. Response of cyclin B1 to ionizing radiation: regulation by NF-kappaB and mitochondrial antioxidant enzyme MnSOD. Anticancer Res. 24(5A):2657–2663.
   PubMed Web of Science ®Google Scholar
• Peinado H, Olmeda D, Cano A. 2007. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 7(6):415–428.
   PubMed Web of Science ®Google Scholar
• Ricca A, Biroccio A, Del Bufalo D, Mackay AR, Santoni A, Cippitelli M. 2000. bcl-2 over-expression enhances NF-kappaB activity and induces mmp-9 transcription in human MCF7(ADR) breast-cancer cells. Int J Cancer. 86(2):188–196.
   PubMed Web of Science ®Google Scholar
• Rübe CE, Wilfert F, Uthe D, Schmid KW, Knoop R, Willich N, Schuck A, Rübe C. 2002. Modulation of radiation-induced tumour necrosis factor alpha (TNF-alpha) expression in the lung tissue by pentoxifylline. Radiother Oncol. 64(2):177–187.
   PubMed Web of Science ®Google Scholar
• Sanders YY, Cui Z, Le Saux CJ, Horowitz JC, Rangarajan S, Kurundkar A, Antony VB, Thannickal VJ. 2015. SMAD-independent down-regulation of caveolin-1 by TGF-β: effects on proliferation and survival of myofibroblasts. PLoS One. 10(2):e0116995.
   PubMed Web of Science ®Google Scholar
• Schiavoni G, Gabriele L, Mattei F. 2013. The tumor microenvironment: a pitch for multiple players. Front Oncol. 3:90.
   PubMedGoogle Scholar
• Schultz N, Marenstein DR, De Angelis DA, Wang WQ, Nelander S, Jacobsen A, Marks DS, Massagué J, Sander C. 2011. Off-target effects dominate a large-scale RNAi screen for modulators of the TGF-β pathway and reveal microRNA regulation of TGFBR2. Silence. 2:3.
   PubMedGoogle Scholar
• Seo N, Hayakawa S, Takigawa M, Tokura Y. 2001. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology. 103(4):449–457.
   PubMed Web of Science ®Google Scholar
• Shirakihara T, Saitoh M, Miyazono K. 2007. Differential regulation of epithelial and mesenchymal markers by deltaEF1 proteins in epithelial mesenchymal transition induced by TGF-beta. Mol Biol Cell. 18(9):3533–3544.
   PubMed Web of Science ®Google Scholar
• Sinha D, Saha P, Samanta A, Bishayee A. 2020. Emerging concepts of hybrid epithelial-to-mesenchymal transition in cancer progression. Biomolecules. 10(11):1561.
   Web of Science ®Google Scholar
• Stuelten CH, DaCosta Byfield S, Arany PR, Karpova TS, Stetler-Stevenson WG, Roberts AB. 2005. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J Cell Sci. 118(Pt 10):2143–2153.
   PubMed Web of Science ®Google Scholar
• Sun Y, Cheng MK, Griffiths TR, Mellon JK, Kai B, Kriajevska M, Manson MM. 2013. Inhibition of STAT signalling in bladder cancer by diindolylmethane: relevance to cell adhesion, migration and proliferation. Curr Cancer Drug Targets. 13(1):57–68.
   PubMed Web of Science ®Google Scholar
• Teixeira AF, Ten Dijke P, Zhu HJ. 2020. On-target anti-TGF-β therapies are not succeeding in clinical cancer treatments: what are remaining challenges? Front Cell Dev Biol. 8(605):605–623.
   PubMedGoogle Scholar
• Theys J, Yahyanejad S, Habets R, Span P, Dubois L, Paesmans K, Kattenbeld B, Cleutjens J, Groot AJ, Schuurbiers O, et al. 2013. High NOTCH activity induces radiation resistance in non small cell lung cancer. Radiother Oncol. 108(3):440–445.
   PubMed Web of Science ®Google Scholar
• Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH, Moustakas A. 2008. HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem. 283(48):33437–33446.
   PubMed Web of Science ®Google Scholar
• Voboril R, Weberova-Voborilova J. 2007. Sensitization of colorectal cancer cells to irradiation by IL-4 and IL-10 is associated with inhibition of NF-kappaB. Neoplasma. 54(6):495–502.
   PubMed Web of Science ®Google Scholar
• Wang SS, Jiang J, Liang XH, Tang YL. 2015. Links between cancer stem cells and epithelial-mesenchymal transition. Onco Targets Ther. 8:2973–2980.
   PubMed Web of Science ®Google Scholar
• Wang LP, Wang YW, Wang BZ, Sun GM, Wang XY, Xu JL. 2014. Expression of interleukin-17A in lung tissues of irradiated mice and the influence of dexamethasone. ScientificWorldJournal. 2014:251067.
   PubMedGoogle Scholar
• Wang X, Zhang X, Qiu C, Yang N. 2020. STAT3 contributes to radioresistance in cancer. Front Oncol. 10:1120.
   PubMed Web of Science ®Google Scholar
• Yadav P, Pandey VK, Shankar BS. 2021. Proteomic analysis of radio-resistant breast cancer xenografts: Increased TGF-β signaling and metabolism. Cell Biol Int. 45(4):804–819.
   PubMed Web of Science ®Google Scholar
• Yadav P, Shankar BS. 2019. Radio resistance in breast cancer cells is mediated through TGF-β signalling, hybrid epithelial-mesenchymal phenotype and cancer stem cells. Biomed Pharmacother. 111:119–130.
   PubMed Web of Science ®Google Scholar
• Zhang M, Kleber S, Röhrich M, Timke C, Han N, Tuettenberg J, Martin-Villalba A, Debus J, Peschke P, Wirkner U, et al. 2011. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res. 71(23):7155–7167.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang YA, Meng A, Yan H, Wang X, Niu J, Li J, Wang H. 2013. Inhibiting TGFβ1 has a protective effect on mouse bone marrow suppression following ionizing radiation exposure in vitro. J Radiat Res. 54(4):630–636.
   PubMed Web of Science ®Google Scholar
• Zhang P, Wei Y, Wang L, Debeb BG, Yuan Y, Zhang J, Yuan J, Wang M, Chen D, Sun Y, et al. 2014. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol. 16(9):864–875.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang L, Huang Q, Jiang Y, Wang J, Zhang L, Tian Y, Yang H. 2016. Radiosensitization of Non-Small Cell Lung Cancer Cells by Inhibition of TGF-β1 Signaling With SB431542 Is Dependent on p53 Status. Oncol Res. 24(1):1–7.
   PubMed Web of Science ®Google Scholar
• Zheng G, Ma Y, Zou Y, Yin A, Li W, Dong D. 2018. HCMDB: the human cancer metastasis database. Nucleic Acids Res. 46(D1):D950–D955.
   PubMed Web of Science ®Google Scholar
• Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL. 2000. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60(6):1541–1545.
   PubMed Web of Science ®Google Scholar
• Zhou HQ, Liu MS, Deng TB, Xie PB, Wang W, Shao T, Wu Y, Zhang P. 2019. The TGF-β/Smad Pathway Inhibitor SB431542 Enhances The Antitumor Effect Of Radiofrequency Ablation On Bladder Cancer Cells. Onco Targets Ther. 12:7809–7821.
   PubMed Web of Science ®Google Scholar